Abstract
BackgroundSystemic administration of tumor necrosis factor-alpha (TNF-α) antagonists, such as infliximab, has been shown to be effective in the treatment of spondyloarthropathies (SpA). However, experience with the local use of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
